Abstract
The in vitro susceptibility of three clinicalTrichophyton rubrum isolates to griseofulvin and tioconazole, determined by the minimal inhibitory concentration (MIC), was 2 and 0.5 to 1.0μg/ml, respectively. One mutant (gril) obtained after mutagenic treatment of one of these isolates was selected and showed simultaneous resistance to griseofulvin (MIC > 2000μg/ml) and tioconazole (MIC=1.0μg/ml). The clinical importance and the possibility of a multidrug resistance (MDR)-type mechanism being involved in this event is discussed.
Similar content being viewed by others
References
Blank H, Roth FJ. The treatment of dermatomycoses with orally administered griseofulvin. Arch Dermatol 1959; 79: 259–266.
Blank H, Smith JG, Roth FJ, et al. Griseofulvin for the systemic treatment of dermatomycoses. Jama 1959; 171: 2168–2174.
Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part I. J Am Acad Dermatol 1994; 30: 677–698.
Grisham LM, Wilson L, Bensch KG. Antimycotic action of griseofulvin does not involve disruption of microtubules. Nature 1973: 244: 294–296.
Gull K, Trinci APJ. Griseofulvin inhibits fungal mitosis. Nature 1973; 244:292–294.
McNall EG. Biochemical studies on the metabolism of griseofulvin. Arch Dermatol 1960; 81: 657–661.
Brian PW. Griseofulvin. Trans Br Mycol Soc 1960; 43: 1–13.
Artis WM, Odle BM, Jones HE. Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch Dermatol 1981; 117: 16–19.
Scholz R, Meinhof W. Susceptibility ofTrichophyton rubrum to griseofulvin. Mycoses 1991; 34: 411–414.
Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part II. J Am Acad Dermatol 1994; 30: 911–933.
Hay RJ, Clayton YM, Moore MK. Tioconazole nail solution: an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111–115.
Kelly SL, Kenna S, Bligh HFJ, Watson PF, Stansfield I, Ellis SW, Kelly DE. Lanosterol to ergosterol — senzymology, inhibition and genetics. In: Kuhn PJ, Trinci APS, Jung MJ, Goosey MW, Copping LG, eds. Biochemistry of walls and membranes in fungi. Germany: Springer-Verlag, 1990: 224–239.
McGinnis MR, ed. Laboratory handbook of Medical Mycology. Academic Press, New York, 1980.
Okeke CN, Gugnani HC. In vitro sensitivity of environmental isolates of pathogenic dermatiaceous fungi to azole compounds and a phenylpropyl-morpholine derivative. Mycopathology 1987; 99: 175–181.
Endicott JA, Ling V. The biochemistry of glycoproteinmediated multidrug resistance. Annu Rev Biochem 1989; 58: 137–171.
Hirata D, Yano K, Miyakawa K, Miyakawa T.Saccharomyces cerevisiae YDR1, which encodes a member of the ATP-binding cassete (ABC) superfamily, is required for multidrug resistance. Curr Genet 1994; 26: 285–294.
Ben-Yaacov R, Knoller S, Caidwell G, Becker JM, Koltin Y.Candida albicans gene encoding resistance to benomyl and methotrexate is a multiresistance gene. Antimicrob Agents Chemother 1994; 38: 648–652.
Clark FS, Parkinson T, Hitchcock CA, Gow NAR. Correlation between Rhodamine 123 accumulation and azole sensitivity inCandida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996; 40: 419–425.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fachin, A.L., Maffei, C.M.L. & Martinez-Rossi, N.M. In vitro susceptibility ofTrichophyton rubrum isolates to griseofulvin and tioconazole. Induction and isolation of a resistant mutant to both antimycotic drugs. Mycopathologia 135, 141–143 (1996). https://doi.org/10.1007/BF00632334
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00632334